Edition:
India

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

7.70USD
2:29am IST
Change (% chg)

$-0.60 (-7.23%)
Prev Close
$8.30
Open
$8.30
Day's High
$8.30
Day's Low
$7.65
Volume
292,814
Avg. Vol
268,852
52-wk High
$15.35
52-wk Low
$4.10

Chart for

About

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $846.68
Shares Outstanding(Mil.): 68.84
Dividend: --
Yield (%): --

Financials

BRIEF-TG Therapeutics qtrly net loss per common share $0.48

* TG therapeutics, inc. Provides business update and reports third quarter 2017 financial results

08 Nov 2017

BRIEF-TG Therapeutics Inc gives results from phase 2 multicenter trial of TG-1101

* TG Therapeutics Inc - ‍announced results from phase 2 multicenter trial of TG-1101 (ublituximab) in relapsing forms of multiple sclerosis​

26 Oct 2017

BRIEF-TG Therapeutics announces completion of full enrollment in UNITY-CLL phase 3 trial

* TG Therapeutics announces completion of full enrollment in the UNITY-CLL phase 3 trial

16 Oct 2017

BRIEF-TG Therapeutics announces completion of target enrollment

* TG Therapeutics announces completion of target enrollment in the unity-CLL phase 3 trial

05 Sep 2017

BRIEF-TG Therapeutics announces successful outcome from first pre-planned interim analysis

* TG Therapeutics Inc announces successful outcome from the first pre-planned interim analysis by independent DSMB of the DLBCL cohort in the unity-NHL PHASE 2B trial

10 Aug 2017

BRIEF-TG Therapeutics Q2 loss per share ‍$0.45​

* Tg therapeutics Inc provides business update and reports second quarter 2017 financial results

09 Aug 2017

BRIEF-TG therapeutics provides FDA update on multiple sclerosis study

* Announces special protocol assessment (spa) agreement with the FDA for a Phase 3 program of TG-1101 (ublituximab) for patients with multiple sclerosis (MS)

01 Aug 2017

BRIEF-TG Therapeutics provides additional data from early-stage cancer drug study

* Tg therapeutics - triple combination of tg-1101, tgr-1202 and bendamustine was generally well-tolerated with only gr 3/4 event >10% being neutropenia

15 Jun 2017

BRIEF-TG Therapeutics says follow-up data for combination of TGR-1202 plus Ibrutinib

* TG Therapeutics, Inc. Announces follow-up data for combination of TGR-1202 (umbralisib) plus ibrutinib in patients with relapsed or refractory cll and mcl at the 14th international conference on malignant lymphoma

14 Jun 2017

Wall Street edges lower as Apple drags

Wall Street edged lower in early afternoon trading on Monday as Apple weighed on all the three major indexes following a rating cut and ahead of its developer conference.

06 Jun 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $138.00 -0.87
Novartis AG (NOVN.S) CHF83.30 +0.90
Roche Holding Ltd. (ROG.S) CHF230.10 +1.10
Roche Holding Ltd. (RO.S) CHF233.30 +1.30
Merck & Co., Inc. (MRK.N) $55.20 +0.03
Bayer AG (BAYGn.DE) €107.55 -0.35
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €75.43 -0.54
Abbott Laboratories (ABT.N) $55.56 +0.02
Alexion Pharmaceuticals, Inc. (ALXN.OQ) $110.87 +0.54

Earnings vs. Estimates